228 related articles for article (PubMed ID: 33090333)
21. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
23. First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.
Moiseyenko VM; Moiseyenko FV; Yanus GA; Kuligina ES; Sokolenko AP; Bizin IV; Kudriavtsev AA; Aleksakhina SN; Volkov NM; Chubenko VA; Kozyreva KS; Kramchaninov MM; Zhuravlev AS; Shelekhova KV; Pashkov DV; Ivantsov AO; Venina AR; Sokolova TN; Preobrazhenskaya EV; Mitiushkina NV; Togo AV; Iyevleva AG; Imyanitov EN
Clin Drug Investig; 2018 Jun; 38(6):553-562. PubMed ID: 29470838
[TBL] [Abstract][Full Text] [Related]
24. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
Santos FA; Reis RM; Barroti LC; Pereira AAL; Matsushita MM; de Carvalho AC; Datorre JG; Berardinelli GN; Araujo RLC
J Gastrointest Cancer; 2024 Mar; 55(1):344-354. PubMed ID: 37608030
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
Taieb J; Balogoun R; Le Malicot K; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Emile JF; Mulot C; Fratté S; Levaché CB; Saban-Roche L; Thaler J; Petersen LN; Bridgewater J; Perkins G; Lepage C; Van Cutsem E; Zaanan A; Laurent-Puig P;
Ann Oncol; 2017 Apr; 28(4):824-830. PubMed ID: 28031175
[TBL] [Abstract][Full Text] [Related]
26. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
27. Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.
Rebersek M; Mesti T; Boc M; Ocvirk J
Radiol Oncol; 2019 Mar; 53(1):85-95. PubMed ID: 30840593
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y
Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609
[TBL] [Abstract][Full Text] [Related]
29. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M; Sadjadian P; Kollmeier J; Lowe J; Mattson P; Trout JR; Gargano M; Patchen ML; Walsh R; Beliveau M; Marier JF; Bose N; Gorden K; Schneller F
Invest New Drugs; 2017 Jun; 35(3):345-358. PubMed ID: 28303530
[TBL] [Abstract][Full Text] [Related]
30. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
31. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
33. A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAF
Georgiou A; Stewart A; Vlachogiannis G; Pickard L; Valeri N; Cunningham D; Whittaker SR; Banerji U
Cell Oncol (Dordr); 2021 Oct; 44(5):1197-1206. PubMed ID: 34462871
[TBL] [Abstract][Full Text] [Related]
34. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Herbst RS; Kelly K; Chansky K; Mack PC; Franklin WA; Hirsch FR; Atkins JN; Dakhil SR; Albain KS; Kim ES; Redman M; Crowley JJ; Gandara DR
J Clin Oncol; 2010 Nov; 28(31):4747-54. PubMed ID: 20921467
[TBL] [Abstract][Full Text] [Related]
35. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab.
Picard A; Pedeutour F; Peyrade F; Saudes L; Duranton-Tanneur V; Chamorey E; Cardot-Leccia N; Sudaka A; Ettaiche M; Benchetrit M; Poissonnet G; Weinbreck N; Dadone B; Lacour JP; Passeron T; Montaudié H
JAMA Dermatol; 2017 Apr; 153(4):291-298. PubMed ID: 28259104
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
Bando H; Yoshino T; Shinozaki E; Nishina T; Yamazaki K; Yamaguchi K; Yuki S; Kajiura S; Fujii S; Yamanaka T; Tsuchihara K; Ohtsu A
BMC Cancer; 2013 Sep; 13():405. PubMed ID: 24006859
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
